3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
39
Nivolumab
15
Gemcitabine
8
spartalizumab
7
atezolizumab
7
Carboplatin
7
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
Cisplatin
5
Bevacizumab
5
fludarabine
4
budigalimab
4
Paclitaxel
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
tislelizumab
3
lenvatinib
3
cemiplimab
3
avelumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
HMPL-013
3
Fulvestrant
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
tinostamustine
×
Gastrointestinal
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts